Participating Companies

Aadi Bioscience
Based on the AM­PECT trial, emerg­ing da­ta for ABI-009 in other solid tu­mors with TSC1 or TSC2 mu­ta­tions, and fol­low­ing dis­cus­sions with the FDA, Aa­di is pro­ceed­ing with a tu­mor-ag­nos­tic reg­is­tra­tio­n­al trial in can­cers har­bor­ing TSC1 or TSC2 patho­genic, in­ac­ti­vat­ing mu­ta­tions with a planned ini­ti­a­tion in 2021. [more in­for­ma­tion]
AavantiBio, Inc.
Aa­vantiBio is a clin­i­cal stage gene ther­a­py com­pany backed by a pre­mi­er syn­di­cate of life sci­ences in­ves­tors in­clud­ing Per­cep­tive Ad­vi­sors, Bain Cap­i­tal Life Sci­ences, and RA Cap­i­tal Ma­n­age­ment, who led the com­pany’s re­cent $107 mil­lion Se­ries A fi­nanc­ing. [more in­for­ma­tion]
Abbisko Therapeutics Co., Ltd.
The com­pany is found­ed by a group of sea­soned drug hun­ters with rich re­search and ma­n­age­ment ex­pe­ri­ence in both top in­ter­na­tio­n­al phar­ma­ceu­ti­cal com­pa­nies and Chi­nese in­dus­trial lead­ers. [more in­for­ma­tion]
Ability Pharmaceuticals, SL
ABTL0812 has been grant­ed Or­phan Drug Desig­na­tion (ODD) for neu­roblas­to­ma, pan­cre­at­ic can­cer and for biliary tract can­cer by FDA and EMA, and the drug has a sales po­ten­tial over &eu­ro;2.5 bil­lion in 2025, with a mar­ket share over 80% in se­lect­ed can­cer types. [more in­for­ma­tion]
Adrenomed AG
Pre­ci­sion medicine, car­dio­vas­cu­lar and Sep­sis, Adre­cizumab Ph 2, bio­mark­er-guid­ed, mon­o­clo­n­al anti­body for sep­tic shock; fi­nal da­ta re­leased late Novem­ber: Ear­ly ap­pli­ca­tion of Adre­cizumab leads to a rapid and sta­tis­ti­cal­ly sig­ni­f­i­cant im­prove­ment of fluid bal­ance, sys­temic or­gan func­tion and > 50% rel­a­tive re­duc­tion of all cause mor­tal­i­ty af­ter 28 days and 90 days com­pared to place­bo on top of SoC. [more in­for­ma­tion]
Pro­pri­e­tary Af­fi­body® molecules and Al­bu­mod® plat­forms. Lead can­di­date ABY-035 is an IL-17 with mul­ti­ple Ph 2 pro­grams (PSO OLE PsA, axS­pA, uvei­tis). Pos­i­tive Ph2 52wk da­ta in pso­ri­a­sis with 2-yr OLE da­ta ex­pect­ed in 2H21. Ph2 in­ter­im da­ta for uvei­tis ex­pect­ed in 2022. AB-251 is a di­ag­nos­tic imag­ing pro­gram that is di­rect­ed pri­mar­i­ly to­wards me­tastat­ic breast can­cer. $81M raised to date. [more in­for­ma­tion]
Akili Interactive Labs
Ak­ili is pi­oneer­ing the de­vel­op­ment of dig­i­tal treat­ments and care so­lu­tions to help peo­ple af­fect­ed by cog­ni­tive im­pair­ments. Ak­ili’s treat­ments are de­signed to di­rect­ly ac­ti­vate the net­works in the brain re­spon­si­ble for cog­ni­tive func­tion and have been ri­g­or­ous­ly test­ed in ex­ten­sive clin­i­cal studies, in­clud­ing prospec­tive ran­domized, con­trolled trials. [more in­for­ma­tion]
AM-Pharma B.V.
Raised $195M in equi­ty and debt in 2019/2020 af­ter re­sults from Ph 2 in 300+ pts de­mon­s­trat­ed ro­bust sig­ni­f­i­cant im­prove­ment of 40%+ OS in re­cAP group. TL safe­ty & fu­til­i­ty anal­y­sis on first 400 pts Q1 2022. Ex­pects to com­plete tgt en­roll­ment & an­nounce pri­mary end­point da­ta of 28-day all-cause mor­tal­i­ty in 2023, or as ear­ly as 2022 based on in­ter­im anal­y­s­es. [more in­for­ma­tion]
Amakos Biotherapeutics, Inc.
Based on much of the pi­oneer­ing re­search from Pro­fes­sor Makriyan­nis it is known that en­do­cann­abi­noids act­ing in the pe­riph­ery are as­so­ci­at­ed with in­flam­ma­tion and fi­bro­sis in a num­ber of dis­eas­es. Dis­cov­ery of the pe­ripher­al­ly se­lec­tive neu­tral an­ta­g­on­ists of the CB-1 re­cep­tor opened the door to new and much safer ap­proach­es to treat lung, kid­ney, and liv­er fi­bro­sis. [more in­for­ma­tion]
Antios Therapeutics
An­tios Ther­a­peu­tics is a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on the de­vel­op­ment of in­no­va­tive ther­a­pies to treat and cure vi­ral dis­eas­es. Da­ta from the Phase 1b study in HVB-in­fect­ed pa­tients are ex­pect­ed to be re­port­ed in 2021.A Phase 2a study (both mono- and com­bi­na­tion ther­a­py) is ex­pect­ed to be ini­ti­at­ed lat­er in 2021. [more in­for­ma­tion]
Aristea Therapeutics
Aris­tea Ther­a­peu­tics (Air-iss-tay-uh) is a clin­i­cal-stage im­munol­o­gy fo­cused drug de­vel­op­ment com­pany de­vel­op­ing nov­el ther­a­pies to treat se­ri­ous in­flam­ma­to­ry dis­eas­es. The Aris­tea team is lev­er­ag­ing its broad in­dus­try ex­per­tise and proven suc­cess in drug de­vel­op­ment to form syn­er­gis­tic part­n­er­ships and build a pipe­line of nov­el drugs. Aris­tea is head­quar­tered in San Die­go, CA. [more in­for­ma­tion]
Our Atom­Net® tech­nol­o­gy has been used to un­lock more un­drug­gable tar­gets than any other AI drug dis­cov­ery plat­form. We are tack­ling over 600 unique dis­ease tar­gets with more than 250 part­n­ers around the world, in­clud­ing lead­ing phar­ma­ceu­ti­cal, agro­chem­i­cal, and emerg­ing biotech­nol­o­gy com­pa­nies. [more in­for­ma­tion]
Austhera Biosciences
Un­lock­ing the FULL promise of poor­ly ab­sorbed drugs and cre­at­ing nov­el NCEs for on­col­o­gy and rare dis­ease, de­liv­er­ing op­ti­mal ther­a­peu­tic ben­e­fit to pa­tients by max­i­miz­ing drug ex­po­sure. Aus­thera al­so has full rights to use Dis­per­Sol’s Kineti­Sol tech­nol­o­gy plat­form in drug dis­cov­ery to find and de­vel­op in­sol­u­ble new chem­i­cal en­ti­ties (NCEs) of sig­ni­f­i­cant ther­a­peu­tic promise. [more in­for­ma­tion]
Bio­Th­eryX is a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on res­tor­ing pro­tein home­os­ta­sis, in­clud­ing pro­tein degra­da­tion and mo­d­u­la­tion, and mul­ti-ki­nase in­hi­bi­tion to de­vel­op treat­ments in­tend­ed to ex­tend and im­prove the qual­i­ty-of-life of pa­tients with life-threat­en­ing dis­eas­es. [more in­for­ma­tion]
Caribou Biosciences
Cari­bou is a lead­ing com­pany in CRIS­PR genome edit­ing found­ed by pi­oneers of CRIS­PR bi­ol­o­gy. The com­pany is de­vel­op­ing an in­ter­nal pipe­line of off-the-shelf CAR-T cell ther­a­pies, other gene-edit­ed na­t­u­ral killer (NK) cell ther­a­pies, and en­gi­neered gut mi­crobes. In­ves­tors in­clude: An­ter­ra Cap­i­tal; Mis­sion Bay Cap­i­tal; No­var­tis [more in­for­ma­tion]
Carisma Therapeutics Inc.
- CARIS­MA Ther­a­peu­tics Inc. is a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing a dif­fer­en­ti­at­ed and pro­pri­e­tary cell ther­a­py plat­form fo­cused on en­gi­neered macrophages, cells that play a cru­cial role in both the in­nate and adap­tive im­mune re­sponse. CARIS­MA Ther­a­peu­tics is head­quar­tered in Philadel­phia, PA. [more in­for­ma­tion]
Celularity [CELU] $790 MM MCap
Celu­lar­i­ty, head­quar­tered in Florham Park, NJ, is a clin­i­cal-stage biotech­nol­o­gy com­pany fo­cus­ing on cel­lu­lar medicine by de­vel­op­ing off-the-shelf pla­cen­tal-de­rived al­lo­gene­ic cell ther­a­pies. Celu­lar­i­ty has a her­i­tage as a former cell-ther­a­py busi­ness unit of Cel­gene. [more in­for­ma­tion]
Cerebral Therapeutics
The com­pany's ther­a­pies uti­l­ize re­for­mu­lat­ed off-pa­tent drugs de­liv­ered to the ven­tri­cles of the brain in or­der to by­pass the blood-brain bar­ri­er, en­abling its clients to re­ceive a re­li­able ap­proach of treat­ing neu­ro­log­i­cal dis­eas­es for which oral in­fused medicines are not able to achieve ad­e­qu­ate con­trol. [more in­for­ma­tion]
Clerio Vision, Inc.
Nov­el oph­thalmic tech­nol­o­gy to treat re­frac­tive er­ror ad­dress­ing mul­ti-bil­lion mar­kets in con­tact lens­es (pres­by­opia, astig­ma­tism, my­opia, my­opia pro­gres­sion) and corneal vi­sion cor­rec­tion (non sur­g­i­cal fla­p­less las­er so­lu­tion). Pres­by­opia con­tact lens 510k sub­mis­sion 2022. Based on No­bel Prize win­n­ing fem­to-se­cond las­er tech­nol­o­gy de­vel­oped by Bausch & Lomb and the Uni­ver­si­ty of Roch­ester. [more in­for­ma­tion]
Crescendo Biologics
Cres­cen­do Bi­o­log­ics is a clin­i­cal stage com­pany de­vel­op­ing T cell en­hanc­ing ther­a­peu­tics. Cres­cen­do’s lead pro­gramme, CB307, is a CD137 (4-1BB) x PS­MA bis­pe­cif­ic. CB307’s unique for­mat de­liv­ers tu­mour-spe­cif­ic killing, while avoid­ing sys­temic toxic­i­ty, and can be ap­plied to a broad range of PS­MA-pos­i­tive can­cer in­di­ca­tions. It is de­signed to cause the pro­lif­er­a­tion of tu­mour-spe­cif­ic T cells, cre­at­ing a safe, broad, longer-last­ing an­ti-tu­mour re­sponse and will be in the clin­ic in ear­ly 2021. [more in­for­ma­tion]
DTx Pharma
De­vel­op­er of an RNA-based ther­a­peu­tics de­signed to aid in per­so­n­al­ized treat­ment across most ther­a­peu­tic ar­eas. The com­pany's tech­nol­o­gy en­ables ef­fi­cient de­liv­ery of nu­cle­ic acid drugs to tis­sues through­out the body, en­abling health­care providers to de­liv­er oli­gos in vi­vo at ther­a­peu­ti­cal­ly rel­e­vant dos­es that work in many cell types in­clud­ing neu­rons, en­dothe­lial and T cells. [more in­for­ma­tion]
EIP Pharma, Inc.
EIP Phar­ma is chart­ing a new course - fo­cused on re­v­ers­ing the sy­nap­tic dys­func­tion that, re­gard­less of the cause, un­der­lies the me­m­o­ry de­fic­its in Alzheimer’s dis­ease. [more in­for­ma­tion]
Elevation Oncology
Our lead can­di­date, serib­an­tumab, in­hibits tu­mor growth driv­en by NRG1 fu­sions and is cur­rent­ly be­ing clin­i­cal­ly test­ed in the Phase 2 CRE­S­TONE study for pa­tients with tu­mors of any ori­gin that have an NRG1 fu­sion. [more in­for­ma­tion]
An Or­gan-Chip is a liv­ing, mi­cro­engi­neered en­vi­ron­ment that re­cre­ates the na­t­u­ral phy­si­ol­o­gy and me­chan­i­cal forces that cells ex­pe­ri­ence within the hu­man body. [more in­for­ma­tion]
ImCheck Therapeutics
ImCheck Ther­a­peu­tics is de­sign­ing and de­vel­op­ing a new gen­er­a­tion of im­munother­a­peu­tic anti­bodies po­si­tioned at the cross­roads of two high-po­ten­tial im­muno­log­i­cal fields: Gam­ma9del­ta2 T cells and bu­ty­rophilins (BTN), a nov­el su­per-fam­i­ly of check­point molecules. [more in­for­ma­tion]
Impact Therapeutics Inc
IM­PACT Ther­a­peu­tics is a pri­vate­ly held clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany and ded­i­cat­ed to the dis­cov­ery and de­vel­op­ment of tar­get­ed an­ti-can­cer ther­a­peu­tics based on syn­thet­ic lethal­i­ty. IM­P7068 is a nov­el Wee1 in­hibi­tor dis­cov­ered and de­vel­oped by IM­PACT Ther­a­peu­tics, with world­wide in­tel­lec­tu­al prop­er­ty, part of in-house DDR franchise. [more in­for­ma­tion]
IN8bio, Inc. [INAB] $110 MM MCap
First com­pany to ad­vance ge­net­i­cal­ly-mod­i­fied gam­ma-del­ta T cells in­to clin­i­cal trials with its Del­tEx Plat­form, based on ex-vi­vo ex­pand­ed and ac­ti­vat­ed gam­ma-del­ta T cells. Two in­vesti­ga­tor-ini­ti­at­ed Phase 1 clin­i­cal trials are un­der­way for lead prod­uct can­di­dates: INB-200 for new­ly di­ag­nosed glioblas­to­ma and INB-100 for acute leukemia. [more in­for­ma­tion]
IO Biotech
IO Biotech is a clin­i­cal stage biotech com­pany de­vel­op­ing dis­rup­tive im­mune ther­a­pies for the treat­ment of can­cer. The pipe­line of first-in-class im­mune mo­d­u­lat­ing an­ti-can­cer ther­a­pies is de­vel­oped by a unique tech­nol­o­gy plat­form, T-win®, en­abling the ac­ti­va­tion of T cells that are spe­cif­ic for im­mune-sup­pres­sive molecules. [more in­for­ma­tion]
ISA Pharmaceuticals BV
is an im­munother­a­py com­pany de­vel­op­ing ra­tio­n­al­ly de­signed, ful­ly syn­thet­ic im­munother­a­peu­tics against can­cer and per­sis­tent vi­ral in­fec­tions. The Com­pany has built a pro­pri­e­tary im­munother­a­py plat­form based on the Syn­thet­ic Long Pep­tide (SLP®) con­cept and AM­PLI­VANT®tech­nol­o­gy. [more in­for­ma­tion]
KAHR is de­vel­op­ing nov­el im­muno-on­col­o­gy fu­sion pro­teins. DSP107, is a CD47-41BB tar­get­ing com­pound aimed at tar­get­ing can­cer cells' in­nate de­fens­es and ac­ti­vat­ing lo­cal­ized re­sponse. Ac­ti­vat­ed path­ways in­clude in­nate and adap­tive im­mu­ni­ty. [more in­for­ma­tion]
Kineta Inc.
Kine­ta (Pri­vate) - whol­ly owned pre­clin­i­cal an­ti-VIS­TA (in­nate im­mune tar­get) anti­body re­pro­grams the tu­mor mi­croen­vi­ron­ment and is dif­fer­en­ti­at­ed from other im­munother­a­pies by block­ing sup­pres­sive cells in cold tu­mors. $360M+ deal with Ge­nen­tech for KCP506, Ph1 non-opi­oid for chron­ic pain. [more in­for­ma­tion]
Kriya Therapeutics
The com­pany us­es al­go­rith­mic tools, scal­able in­fras­truc­ture, and pro­pri­e­tary tech­nol­o­gy to op­ti­mize the ef­fi­ca­cy and dura­bil­i­ty of our gene ther­a­pies, there­by en­abling health­care in­sti­tu­tions to pro­vide trans­for­ma­tive new treat­ments for high­ly pre­va­lent and se­vere chron­ic dis­eas­es. [more in­for­ma­tion]
Maxwell Biosciences
Maxwell is de­vel­op­ing a com­plete­ly new drug class, Claromers™️, which have been proven to de­stroy a broad range of virus­es in­clud­ing In­fluen­za A, He­p­ati­tis B & C, Coro­n­aVirus strains in­clud­ing all test­ed strains of SARS-CoV-2. [more in­for­ma­tion]
MiNA Therapeutics
Ver­satile, pro­pri­e­tary small ac­ti­vat­ing ri­bonu­cle­ic acid (saR­NA) ther­a­peu­tics plat­form and in­ter­nal pipe­line, ini­tial­ly fo­cus­ing on on­col­o­gy and rare dis­ease in­di­ca­tions. Ini­ti­at­ing ran­domized Ph2 study for lead saR­NA drug can­di­date MTL-CEB­PA com­bined with so­rafenib in 2L HCC in 4Q21. $1.5B+ phar­ma part­n­er­ships. [more in­for­ma­tion]
Minoryx Therapeutics
Oral PPARg ag­on­ist, lerigl­i­ta­zone, de­mon­s­trat­ed clin­i­cal ben­e­fit of sig­ni­f­i­cant­ly re­duc­ing pro­gres­sion of cere­bral le­sions and myelo­pa­thy symp­toms in piv­o­tal Phase 2/3 study re­sults in X-ALD pts w Adreno­myeloneu­ro­pa­thy (AMN), 6MWT end­point was not met; on­go­ing dis­cus­sions with reg­u­la­tors re: ap­pro­val. Phase 2 da­ta in Frie­drich’s Ataxia showed mo­d­u­la­tion of the Fra­taxin path­way and res­to­ra­tion of the bioen­er­get­ics de­fic­its in FR­DA pa­tients. VC in­ves­tors in­clude Kur­ma, Ysios, Fund+, Roche, Id­in­vest, etc [more in­for­ma­tion]
Nocion Therapeutics
The com­pany’s mis­sion is to safe­ly alle­vi­ate suf­fer­ing for mil­lions of pa­tients with con­di­tions aris­ing from ac­ti­vat­ed sen­so­ry neu­rons. [more in­for­ma­tion]
Notch Therapeutics
Notch’s tech­nol­o­gy plat­form us­es ge­net­i­cal­ly tailored stem cells as a re­ne­w­able source for cre­at­ing al­lo­gene­ic T cell ther­a­pies that ex­pand treat­ment op­tions and has the po­ten­tial to de­liv­er safer, con­sis­tent­ly man­u­fac­tured and more cost-ef­fec­tive cell im­munother­a­pies to pa­tients. [more in­for­ma­tion]
Nouscom AG
Nous­com is a next-gen­er­a­tion im­munother­a­py com­pany de­vel­op­ing ge­net­ic neoanti­gen vaccines and on­co­lyt­ic virus­es for pre­ven­tion and treat­ment of can­cer. The com­pany has of­fices in Basel and Rome. [more in­for­ma­tion]
Numab Therapeutics
We are writ­ing the next chapter in can­cer im­munother­a­py by cre­at­ing mul­ti-spe­cif­ic anti­bodies that en­able the pur­suit of nov­el ther­a­peu­tic strate­gies. With our pro­pri­e­tary MATCH™ tech­nol­o­gy plat­form we are fu­el­ing a new wave of mul­ti-spe­cif­ic drug can­di­dates en­gi­neered with ver­satil­i­ty and de­vel­o­pa­bil­i­ty in mind. [more in­for­ma­tion]
Omega Therapeutics
About Ome­ga Ther­a­peu­tics Ome­ga Ther­a­peu­tics is a pri­vate­ly held, de­vel­op­ment-stage biotech­nol­o­gy com­pany pi­oneer­ing the field of epige­nom­ic pro­gram­ming to pre­cise­ly reg­u­late and con­trol the hu­man genome to treat and cure dis­ease. [more in­for­ma­tion]
OncXerna Therapeutics
On­cX­er­na Ther­a­peu­tics of­fers a unique ap­proach to pre­ci­sion on­col­o­gy medicine based on a deep un­der­s­tand­ing of a pa­tient’s solid tu­mor mi­croen­vi­ron­ment and “dom­i­nant bi­ol­o­gy” at the RNA lev­el. [more in­for­ma­tion]
SAB Biotherapeutics
SAB's plat­form shows promise with mul­ti-tar­get­ing ca­pa­bil­i­ty to uti­l­ize a mul­ti­va­lent po­ly­clo­n­al ap­proach for the first time in on­col­o­gy. [more in­for­ma­tion]
Sapience Therapeutics
Th­ese tar­gets are con­sid­ered un­drug­gable be­cause they are PPIs that re­side in­side of the cell, mak­ing them dif­fi­cult to treat with small molecule drugs such as che­mother­a­pies (which are in­ca­pable of dis­rupt­ing PPIs) or bi­o­log­ic-based drugs such as mon­o­clo­n­al anti­bodies (which are too big to en­ter the cell). [more in­for­ma­tion]
Tarveda Therapeutics
is dis­cov­er­ing and de­vel­op­ing a new class of po­tent and se­lec­tive mi­nia­ture drug con­ju­gates (Pen­tarins®) for the treat­ment of pa­tients with a wide range of solid tu­mors. PEN-221 is a mi­nia­ture drug con­ju­gate in clin­i­cal eval­u­a­tion for the treat­ment of pa­tients with so­ma­to­s­tatin re­cep­tor 2 (SSTR2) ex­press­ing neu­roen­docrine, small cell lung and other solid tu­mors. [more in­for­ma­tion]
Tempest Therapeutics
Tem­pest Ther­a­peu­tics is a de­vel­op­men­t‐s­tage biotech­nol­o­gy com­pany ad­vanc­ing small molecules that mo­d­u­late an­ti‐­tu­mor im­mu­ni­ty path­ways. The com­pany has a bal­anced and deep pipe­line con­sist­ing of first‐in‐­class and po­ten­tial best‐in‐­class small molecule ther­a­peu­tics that mo­d­u­late dist­inct im­mune re­sponse path­ways rel­e­vant to mount­ing an ef­fec­tive an­ti‐­tu­mor re­sponse. [more in­for­ma­tion]
Triplet Therapeutics
Tri­plet is pur­su­ing a trans­for­ma­tive ap­proach to de­vel­op treat­ments for re­peat ex­pan­sion di­s­or­ders, a group of more than 40 known ge­net­ic dis­eas­es as­so­ci­at­ed with ex­pand­ed DNA nu­cleotide re­peats in­clud­ing Hunt­ing­ton’s dis­ease, my­o­ton­ic dys­tro­phy and vari­ous spino­cere­bel­lar ataxias. [more in­for­ma­tion]
Triumvira Immunologics
The com­pany's pro­pri­e­tary tech­nol­o­gy re­cruits the en­tire na­t­u­ral T-cell re­cep­tor and func­tions in­de­pen­dent of the Ma­jor His­to­com­pat­i­bil­i­ty Com­plex (MHC), po­ten­tial­ly al­low­ing for the de­vel­op­ment of bet­ter ther­a­pies for a broad­er range of pa­tients with solid or liquid ma­lig­nan­cies and with dis­eas­es other than can­cer, there­by pro­vid­ing med­i­cal prac­ti­tion­ers and pa­tients with new hope to deal with life-threat­en­ing dis­eas­es. [more in­for­ma­tion]
Vedanta Biosciences
De­vel­op­ing an in­no­va­tive class of ther­a­pies that mo­d­u­late path­ways of in­ter­ac­tion be­tween the hu­man mi­cro­biome and the host im­mune sys­tem. Ve­dan­ta Bio­s­ciences was co-found­ed by PureTech and a group of world renowned ex­perts in im­munol­o­gy and mi­cro­bi­ol­o­gy. [more in­for­ma­tion]
Vestaron Corporation
Ves­taron has earned glob­al recog­ni­tion for its work, in­clud­ing the inau­gu­ral 2015 Ber­nard Blum Award for nov­el bio­con­trol so­lu­tions, a 2020 THRIVE Top 50 Growth-Stage hon­oree, and the presti­gious Green Chem­istry Chal­lenge Award from the U.S. En­vi­ron­men­tal Pro­tec­tion Agen­cy and the Amer­i­can Chem­i­cal So­ci­e­ty Green Chem­istry In­sti­tute in 2020. [more in­for­ma­tion]